Karmanos Cancer Institute

Site:	Karmanos Cancer Institute	Go to their website
Address:	4100 John R
City:	Detroit
State:	MI
Zip:	48201
Country:	USA

15 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
1	Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors	Ongoing, but not recruiting	Closed	XL765	NCT00485719
3	Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg Imatinib)	Terminated	Closed	Sunitinib or Imatinib	NCT00372567
1	Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	STA-9090	NCT00688116
1	PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors	Completed	Closed	PLX9486 + PLX3397	NCT02401815
1	A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 + Pembrolizumab	NCT02452424
1	Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Active, not recruiting	Closed	Nivolumab + BMS-986016	NCT01968109
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
1	A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEDI-573	NCT00816361
1	Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor	Completed	Closed	KW2450	NCT00921336
1	IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678769
1	A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	Ongoing, but not recruiting	Closed	GDC-0973 + GDC-0068	NCT01562275
1	A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors	Completed	Closed	GDC-0941 + GDC-0973	NCT00996892
1	A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable	Ongoing, but not recruiting	Closed	GDC-0941	NCT00876109
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267